AB SCIEX QTRAP 5500 System

AB SCIEX QTRAP 5500 系统

• 批准号: 7793764
• 负责人: Sharyn D Baker
• 金额: $ 40.5万
• 依托单位: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-22 至 2011-04-21
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7793764
• 关键词: Acute Lymphocytic Leukemia; Antineoplastic Agents; Arts; Biological; Biological Assay; Chemicals; Child; Development; Disease; Drug Kinetics; Ependymoma; Equipment; Funding; Glioma; Innovative Therapy; Lead; Malignant Childhood Neoplasm; Malignant Neoplasms; Mass Spectrum Analysis; Mission; Modality; Modeling; Molecular Genetics; Peer Review; Pharmacodynamics; Pre-Clinical Model; Research; Research Personnel; Retinoblastoma; Saint Jude Children' s Research Hospital; Sampling; Solid Neoplasm; Specificity; System; Therapeutic; Translational Research; Translations; analytical method; base; drug discovery; indexing; innovation; insight; medulloblastoma; novel; pre-clinical; programs; public health relevance; small molecule

DESCRIPTION (provided by applicant): The primary mission of St. Jude Children's Research Hospital is to find cures for children with cancer and other catastrophic diseases through research and treatment. Recent progress at St. Jude has provided a better understanding of the molecular, genetic and chemical bases of cancer in children. These findings have provided new insights into novel targets and treatment modalities for multiple cancers. An extensive therapeutic drug discovery program at St. Jude has identified lead compounds to evaluate in novel preclincial models of childhood cancer. The long-term objective of this application is to support the preclinical development of novel small molecules and their translation to innovative strategies for childhood cancers including acute lymphoblastic leukemia, ependymoma, medulloblastoma, glioma, retinoblastoma and other solid tumors. With the proposed state-of-the-art LC/MS/MS system, the specific aim is to develop, validate and implement sensitive and specific analytical methods for anticancer agents, their metabolites, or other relevant pharmacologic indices in biological samples to facilitate high-quality pharmacokinetic/ pharmacodynamic translational research in pre-clinical models at St. Jude. The proposed equipment will benefit five competitively funded peer-reviewed investigators and their projects through greater assay selectivity, specificity, efficiency, and consistency in application of state-of-the-art equipment and approaches to preclinical pharmacokinetic projects. PUBLIC HEALTH RELEVANCE: Recent progress at St. Jude has provided a better understanding of the molecular, genetic and chemical bases of cancer in children. This project will provide state-of-the-art analytical methods based on mass spectrometry to support the preclinical development of novel small molecules and their translation to innovative therapies for children with cancer.

描述(申请人提供)：圣犹大儿童研究医院的主要任务是通过研究和治疗为患有癌症和其他灾难性疾病的儿童找到治疗方法。圣犹大的最新进展使人们对儿童癌症的分子、遗传和化学基础有了更好的了解。这些发现为多种癌症的新靶点和治疗方式提供了新的见解。圣裘德大学的一项广泛的治疗药物发现计划已经确定了先导化合物，用于评估儿童癌症的新的临床前模型。该应用的长期目标是支持新型小分子的临床前开发，并将其转化为儿童癌症的创新策略，包括急性淋巴细胞性白血病、室管膜瘤、髓母细胞瘤、胶质瘤、视网膜母细胞瘤和其他实体肿瘤。利用拟议的最先进的LC/MS/MS系统，具体目标是开发、验证和实施对生物样本中的抗癌药物、其代谢物或其他相关药理学指标的灵敏和特异的分析方法，以促进圣裘德大学临床前模型的高质量药代动力学/药效学转化研究。建议中的设备将通过在临床前药代动力学项目中应用最先进的设备和方法方面的更高的分析选择性、特异性、效率和一致性，使五名竞争对手资助的同行评审研究人员及其项目受益。 公共卫生相关性：圣犹大的最新进展使人们更好地了解儿童癌症的分子、遗传和化学基础。该项目将提供基于质谱学的最先进的分析方法，以支持新的小分子的临床前开发，并将其转化为癌症儿童的创新疗法。